SI20108B - A controlled release formulation for poorly soluble basic drugs - Google Patents
A controlled release formulation for poorly soluble basic drugs Download PDFInfo
- Publication number
- SI20108B SI20108B SI9720096A SI9720096A SI20108B SI 20108 B SI20108 B SI 20108B SI 9720096 A SI9720096 A SI 9720096A SI 9720096 A SI9720096 A SI 9720096A SI 20108 B SI20108 B SI 20108B
- Authority
- SI
- Slovenia
- Prior art keywords
- composition
- alginate
- sodium
- salt
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 17
- 239000003814 drug Substances 0.000 title claims abstract 8
- 238000013270 controlled release Methods 0.000 title claims abstract 4
- 229940079593 drug Drugs 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 235000010443 alginic acid Nutrition 0.000 claims abstract 4
- 239000000783 alginic acid Substances 0.000 claims abstract 4
- 229960001126 alginic acid Drugs 0.000 claims abstract 4
- 229920000615 alginic acid Polymers 0.000 claims abstract 4
- 150000004781 alginic acids Chemical class 0.000 claims abstract 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical class O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002626 clarithromycin Drugs 0.000 claims abstract 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000007787 solid Substances 0.000 claims abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 8
- 239000000661 sodium alginate Substances 0.000 claims 8
- 235000010413 sodium alginate Nutrition 0.000 claims 8
- 229940005550 sodium alginate Drugs 0.000 claims 8
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 claims 5
- 239000000648 calcium alginate Substances 0.000 claims 5
- 235000010410 calcium alginate Nutrition 0.000 claims 5
- 229960002681 calcium alginate Drugs 0.000 claims 5
- 150000001735 carboxylic acids Chemical class 0.000 claims 4
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- IWTSXJNGTTXMFK-KTQUSEMZSA-N (2r,3s,4r,5r,8r,9s,10s,11r,12r)-5-ethyl-11-[(2s,3r,4s,6r)-4-[ethyl(methyl)amino]-3-hydroxy-6-methyloxan-2-yl]oxy-3-hydroxy-9-[(2s,4s,6s)-4-methoxy-4,6-dimethyloxan-2-yl]oxy-2,4,8,10,12,14-hexamethyl-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C2=C(C)C[C@](O2)(C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)CC)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)C[C@H](C)O1 IWTSXJNGTTXMFK-KTQUSEMZSA-N 0.000 claims 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000011437 Amygdalus communis Nutrition 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 241000220304 Prunus dulcis Species 0.000 claims 1
- 235000020224 almond Nutrition 0.000 claims 1
- 229960002274 atenolol Drugs 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 1
- 229960001380 cimetidine Drugs 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- -1 dithromycin Chemical compound 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- 229960004569 indapamide Drugs 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 229960005224 roxithromycin Drugs 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims 1
- 229960005404 sulfamethoxazole Drugs 0.000 claims 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A controlled release, oral, solid, pharmaceutical composition for a reduced daily dosage regimen is described where the therapeutic ingredient is a poorly soluble basic drug. The formulation comprises the use of a water-soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid in admixture with the therapeutic drug. A particular embodiment comprising a once a day dosage form for clarithromycin is also described.
Claims (17)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1997/010705 WO1998056357A1 (en) | 1995-12-19 | 1997-06-11 | A controlled release formulation for poorly soluble basic drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20108A SI20108A (en) | 2000-06-30 |
| SI20108B true SI20108B (en) | 2001-12-31 |
Family
ID=22261117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9720096A SI20108B (en) | 1997-06-11 | 1997-06-11 | A controlled release formulation for poorly soluble basic drugs |
Country Status (4)
| Country | Link |
|---|---|
| NO (1) | NO310095B1 (en) |
| SI (1) | SI20108B (en) |
| SK (1) | SK282427B6 (en) |
| WO (1) | WO1998056357A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000066174A2 (en) * | 1999-04-29 | 2000-11-09 | Russinsky Limited | Compounds |
| EP1118333A1 (en) * | 2000-01-18 | 2001-07-25 | Eurand International S.P.A. | Compositions with enhanced oral bioavailability |
| CN100341886C (en) * | 2000-11-27 | 2007-10-10 | 桑多斯股份公司 | Macrolide solvates |
| EP1492504A2 (en) * | 2002-04-03 | 2005-01-05 | Ranbaxy Laboratories, Ltd. | Taste masked compositions of erythromycin a and derivatives thereof |
| SI21300A (en) * | 2002-10-08 | 2004-04-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical compositions with alginates |
| CN100336511C (en) * | 2002-11-15 | 2007-09-12 | 江苏豪森药业股份有限公司 | Release-controlled oral Roxithromycin formulation |
| EP1638529B1 (en) * | 2003-06-16 | 2016-08-10 | ANDRX Pharmaceuticals, LLC. | Oral extended-release composition |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| BRPI0417348A (en) | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | spray gelatinization process using an extruder for preparing multiparticulate crystalline drug compositions preferably containing a poloxamer and a glyceride |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| WO2016033556A1 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS |
| US20160361322A1 (en) | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
| EP3544614B1 (en) | 2016-11-28 | 2025-12-31 | Lipocine Inc. | ORAL TESTOSTERONE UNDECANOATE THERAPY |
| JP2021531348A (en) | 2018-07-20 | 2021-11-18 | リポシン，インク． | Liver disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60163823A (en) * | 1984-02-03 | 1985-08-26 | Taisho Pharmaceut Co Ltd | Orally administered formulation |
| EP0188040B1 (en) * | 1985-01-11 | 1991-08-14 | Abbott Laboratories Limited | Slow release solid preparation |
| US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
-
1997
- 1997-06-11 SI SI9720096A patent/SI20108B/en unknown
- 1997-06-11 WO PCT/US1997/010705 patent/WO1998056357A1/en not_active Ceased
- 1997-06-11 SK SK1612-99A patent/SK282427B6/en not_active IP Right Cessation
-
1999
- 1999-12-13 NO NO996161A patent/NO310095B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SK161299A3 (en) | 2000-05-16 |
| NO996161L (en) | 1999-12-13 |
| NO310095B1 (en) | 2001-05-21 |
| NO996161D0 (en) | 1999-12-13 |
| SI20108A (en) | 2000-06-30 |
| WO1998056357A1 (en) | 1998-12-17 |
| SK282427B6 (en) | 2002-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20108B (en) | A controlled release formulation for poorly soluble basic drugs | |
| RU97112089A (en) | SOLID PHARMACEUTICAL COMPOSITION WITH REGULATED MEDICINAL RELEASE | |
| UA40663C2 (en) | controlled release, solid pharmaceutical composition adapted for oral administration | |
| US5646131A (en) | Method for solubilizing drugs using cyclodextrins and carboxylic acids | |
| EP0792147B1 (en) | Pharmaceutical composition comprising non-steroidal anti-inflammatory drugs | |
| CA2337046A1 (en) | Sustained release pharmaceutical preparation | |
| US5736573A (en) | Lipid and water soluble derivatives of drugs | |
| RU2333745C2 (en) | Compositions with controlled liberation | |
| JPH0229052B2 (en) | ||
| HRP20010243B1 (en) | PREPARATIONS CONTAINING DIPHOSPHONIC ACIDS | |
| PL295329A1 (en) | Method of improving oral administration applicability of a biological medication substance: dideoxypurin nucleoside | |
| ES2235834T3 (en) | DIRECTLY COMPRIMIBLE MATRIX FOR THE CONTROLLED RELEASE OF SINGLE DAILY DOSE OF CLARITROMYCIN. | |
| US3865935A (en) | Tableting of erythromycin base | |
| EP0531524B1 (en) | Sustained release suppository | |
| CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
| JPH1192402A (en) | Formulation composition and its production | |
| SK42999A3 (en) | Aqueous liquid pharmaceutical formulation, process for the preparation and use thereof | |
| WO2003037304B1 (en) | Controlled release compositions for macrolide antimicrobial agents | |
| EP0271151A3 (en) | Azumolene dosage form | |
| AU749509B2 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| Csemiczky et al. | Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin) | |
| Vandamme et al. | Controlled release of levamisole from poly-(ε-caprolactone) matrices II. Effects of water-soluble polymer and iron powder incorporated into the matrices | |
| US7345024B2 (en) | Pharmaceutical preparation, method for its production as well as its use | |
| EA199900938A1 (en) | METHOD FOR PREPARING A STABLE PHARMACEUTICAL COMPOSITION WITH FIXED DOSING FROM ANTIINFECTIVE AGENT / AGENTS AND MICROORGANISMS AS ACTIVE INGREDIENTS | |
| YU25297A (en) | A controlled release formulation for poorly soluble basic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the prs date | ||
| SP73 | Change of data on owner |
Owner name: BGP PRODUCTS OPERATIONS GMBH; CH Effective date: 20160404 |